Imaging of multidrug resistance in cancer.
Imaging of multidrug resistance in cancer.
复制标题
DOI：
10.1102/1470-7330.2011.0001
复制
发表时间：
2011-03-01
期刊：
影响因子：
--
通讯作者：
Peters AM
中科院分区：
文献类型：
--
作者：
Dizdarevic S;Peters AM
原发性内在和/或获得性多药耐药（MDR）是成功治疗癌症的主要障碍。使用单光子或正电子发射器对癌症MDR进行功能性分子成像可能有助于识别多药耐药肿瘤，不仅可以预测那些对治疗有抗性的患者，临床预后不良，而且还可以预测那些容易发生药物毒性甚至某些肿瘤的患者。mdr 1基因产物的变异可能直接影响治疗效果，mdr 1基因的单核苷酸多态性可能与改变MDR 1底物的口服生物利用度、耐药性和对某些人类疾病的易感性相关。在体内翻译MDR调节概念的挑战涉及恶性细胞和正常细胞之间的复杂细胞相互作用。功能性单光子发射断层扫描或正电子发射断层扫描成像结果与mdr 1基因型和临床数据的整合和相关性可能有助于通过选择具有适当分子表型的癌症患者以获得最大个体治疗益处以及那些无应答者来进行有效管理。本文综述了功能成像的MDR的经典机制的作用，重点是现成的[99 mTc]MIBI放射成像。MIBI放射成像已被证明是一种非侵入性的成本效益的体内检测与肿瘤MDR相关的ATP结合盒转运蛋白，包括P-糖蛋白，多药耐药蛋白1和乳腺癌耐药蛋白。针对分子靶点（如血管内皮生长因子和HER 2受体）的新型成像剂可能与MDR成像底物结合，以更准确地预测对抗癌药物的治疗反应，指导个性化治疗，同时最大限度地降低个性化医疗时代无效治疗的经济健康成本。
Primary intrinsic and/or acquired multidrug resistance (MDR) is the main obstacle to successful cancer treatment. Functional molecular imaging of MDR in cancer using single photon or positron emitters may be helpful to identify multidrug-resistant tumours and predict not only those patients who are resistant to treatment, with a clinically unfavourable prognosis, but also those who are susceptible to the development of drug toxicity or even certain tumours . Variations in the mdr1 gene product may directly affect the therapeutic effectiveness, and single nucleotide polymorphisms for the mdr1 gene may be associated with altered oral bioavailability of MDR1 substrates, drug resistance, and a susceptibility to some human diseases. The challenge of translating the concept of MDR modulation in vivo involves a complex cellular interplay between both malignant and normal cells. Integration and correlation of functional single photon emission tomography or positron emission tomography imaging findings with mdr1 genotype and clinical data may contribute to efficient management by selecting cancer patients with the appropriate molecular phenotype for maximal individual therapeutic benefit, as well as those who are non-responders. This review describes a role for functional imaging of classical mechanisms of MDR with an emphasis on readily available [99mTc]MIBI scintigraphy. MIBI scintigraphy has been shown to be a non-invasive cost-effective in vivo assay of ATP-binding cassette transporters associated with MDR in cancer, including P-glycoprotein, multidrug-resistant protein 1 and breast cancer resistant protein. New imaging agents for molecular targets such as vascular endothelial growth factor and HER2 receptors, may potentially be combined with MDR imaging substrates to more accurately predict the therapeutic response to anticancer drugs, guiding individualised treatment while minimising the economic health costs of ineffective therapy in an era of personalised medicine.
登录
查看更多内容
影响因子：
11.5
作者：
Kawata, K;Kanai, M;Takabayashi, A
通讯作者：
Takabayashi, A
DOI：
10.1126/science.1168750
发表时间：
2009-03-27
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Aller SG;Yu J;Ward A;Weng Y;Chittaboina S;Zhuo R;Harrell PM;Trinh YT;Zhang Q;Urbatsch IL;Chang G
通讯作者：
Chang G
DOI：
10.1007/978-1-60761-416-6_14
发表时间：
2010-01-01
期刊：
MULTI-DRUG RESISTANCE IN CANCER
影响因子：
--
作者：
Lee, Chow H.
通讯作者：
Lee, Chow H.
影响因子：
6.7
作者：
Cascorbi, I;Gerloff, T;Roots, I
通讯作者：
Roots, I
影响因子：
19.6
作者：
Koziolek, MJ;Riess, R;Hauser, IA
通讯作者：
Hauser, IA